Dr. Lal PathLabs (LALPATHLAB) Stock Overview
Operates laboratories for carrying out pathological investigations in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
LALPATHLAB Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Dr. Lal PathLabs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹3,179.60 |
| 52 Week High | ₹3,653.95 |
| 52 Week Low | ₹2,293.55 |
| Beta | 0.062 |
| 1 Month Change | -2.15% |
| 3 Month Change | 10.40% |
| 1 Year Change | -8.10% |
| 3 Year Change | 33.91% |
| 5 Year Change | 45.90% |
| Change since IPO | 285.41% |
Recent News & Updates
Here's Why We Think Dr. Lal PathLabs (NSE:LALPATHLAB) Is Well Worth Watching
Sep 29
Under The Bonnet, Dr. Lal PathLabs' (NSE:LALPATHLAB) Returns Look Impressive
Sep 01Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Aug 18Dr. Lal PathLabs Limited Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next
Aug 05Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Shares May Have Run Too Fast Too Soon
Jul 25Recent updates
Here's Why We Think Dr. Lal PathLabs (NSE:LALPATHLAB) Is Well Worth Watching
Sep 29Under The Bonnet, Dr. Lal PathLabs' (NSE:LALPATHLAB) Returns Look Impressive
Sep 01Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Aug 18Dr. Lal PathLabs Limited Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next
Aug 05Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Shares May Have Run Too Fast Too Soon
Jul 25Is Now The Time To Put Dr. Lal PathLabs (NSE:LALPATHLAB) On Your Watchlist?
Jun 24Dr. Lal PathLabs (NSE:LALPATHLAB) Has Affirmed Its Dividend Of ₹6.00
Jun 03Dr. Lal PathLabs (NSE:LALPATHLAB) Has Affirmed Its Dividend Of ₹6.00
Apr 28Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Business Is Trailing The Market But Its Shares Aren't
Apr 25Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong
Mar 04
Expansion Into Tier 2 And Tier 3 Towns Will Enhance Access To Diagnostic Services In India
Government health spending and rising NCD prevalence are likely to boost Dr. Lal PathLabs' patient volumes and revenues.Analyst Estimates: Here's What Brokers Think Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) After Its Third-Quarter Report
Feb 03Investor Optimism Abounds Dr. Lal PathLabs Limited (NSE:LALPATHLAB) But Growth Is Lacking
Jan 16These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Jan 01Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results
Oct 26Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong
Oct 24Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk
Oct 06These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Jul 28We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve
May 21What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You
May 01Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Apr 13These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Mar 06Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next
Feb 04Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price
Dec 28Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Nov 17Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around
Oct 12Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly
Jul 07Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Jun 10Shareholder Returns
| LALPATHLAB | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | 1.5% | -0.4% | 1.5% |
| 1Y | -8.1% | 21.4% | -4.7% |
Return vs Industry: LALPATHLAB underperformed the Indian Healthcare industry which returned 21.4% over the past year.
Return vs Market: LALPATHLAB underperformed the Indian Market which returned -4.7% over the past year.
Price Volatility
| LALPATHLAB volatility | |
|---|---|
| LALPATHLAB Average Weekly Movement | 3.7% |
| Healthcare Industry Average Movement | 4.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.3% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: LALPATHLAB has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: LALPATHLAB's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 4,980 | Shankha Banerjee | www.lalpathlabs.com |
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs.
Dr. Lal PathLabs Limited Fundamentals Summary
| LALPATHLAB fundamental statistics | |
|---|---|
| Market cap | ₹261.20b |
| Earnings (TTM) | ₹5.13b |
| Revenue (TTM) | ₹25.29b |
Is LALPATHLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LALPATHLAB income statement (TTM) | |
|---|---|
| Revenue | ₹25.29b |
| Cost of Revenue | ₹10.62b |
| Gross Profit | ₹14.67b |
| Other Expenses | ₹9.54b |
| Earnings | ₹5.13b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 61.45 |
| Gross Margin | 57.99% |
| Net Profit Margin | 20.29% |
| Debt/Equity Ratio | 7.1% |
How did LALPATHLAB perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/06 11:35 |
| End of Day Share Price | 2025/10/06 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dr. Lal PathLabs Limited is covered by 52 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ashwin Mehta | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| Prashant Nair | Ambit Capital |